1-5 of 5
Lisa Williams
Close
Sort by
Journal Articles

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Luciano J. Costa, MD PhD, Heather Landau, MD, Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Donna Salzman, MD, Ayman Saad, MD, Racquel Innis-Shelton, MD, Mehdi Hamadani, MD, Roni Tamari, MD, Kelly N. Godby, MD, Vladimir Petrovic, Lisa Williams, RN, Evelyn Orlando, Pamela M Dixon, RN, Sergio A. Giralt, MD
Journal: Blood
Blood (2016) 128 (22): 4630.
https://doi.org/10.1182/blood.V128.22.4630.4630
Published: 2016
Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Anas Younes, MD, Gilles Salles, Giovanni Martinelli, R. Gregory Bociek, MD, Dolores Caballero Barrigon, MD, Eva Gonzalez Barca, Mehmet Turgut, MD PhD, John F. Gerecitano, MD, Fabian Herbst, Lisa Williams, Nabanita Mukherjee, Ranjana Tavorath, Won Seog Kim, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1493.
https://doi.org/10.1182/blood.V126.23.1493.1493
Published: 2015
Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Anas Younes, Gilles Salles, MDPhD, R. Gregory Bociek, MD, Giovanni Martinelli, Dolores Caballero, Eva González Barca, Nabanita Mukherjee, Lisa Williams, Fabian Herbst, Ranjana Tavorath, Won Seog Kim
Journal: Blood
Blood (2014) 124 (21): 1718.
https://doi.org/10.1182/blood.V124.21.1718.1718
Published: 2014
Journal Articles

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Racquel Innis-Shelton, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Lawrence S. Lamb, PhD, Melissa Gazi, Lisa Williams, RN, Luciano J Costa, MD PhD, Harry Erba, Shin Mineishi, MD, Ayman Saad, MD
Journal: Blood
Blood (2014) 124 (21): 3911.
https://doi.org/10.1182/blood.V124.21.3911.3911
Published: 2014
Journal Articles

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Brian Leber, MD, Nelson Spector, MD, PhD, Francisco Cervantes, MD, PhD, Ricardo Pasquini, MD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Suzanne Kamel-Reid, PhD, Israel Bendit, MD, John Reynolds, PhD, Lisa Williams, Tomasz Szczudlo, Susan Branford, PhD
Journal: Blood
Blood (2011) 118 (21): 606.
https://doi.org/10.1182/blood.V118.21.606.606
Published: 2011